KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Preferred Stock Liabilities (2023 - 2025)

Evolent Health (EVH) has 3 years of Preferred Stock Liabilities data on record, last reported at $228.8 million in Q2 2025.

  • For Q2 2025, Preferred Stock Liabilities rose 24.21% year-over-year to $228.8 million; the TTM value through Jun 2025 reached $228.8 million, up 24.21%, while the annual FY2024 figure was $190.2 million, 6.58% up from the prior year.
  • Preferred Stock Liabilities reached $228.8 million in Q2 2025 per EVH's latest filing, up from $193.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $228.8 million in Q2 2025 and bottomed at $170.6 million in Q1 2023.
  • Average Preferred Stock Liabilities over 3 years is $186.2 million, with a median of $182.8 million recorded in 2024.
  • Peak YoY movement for Preferred Stock Liabilities: increased 6.25% in 2024, then increased 24.21% in 2025.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $178.4 million in 2023, then rose by 6.58% to $190.2 million in 2024, then increased by 20.31% to $228.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Stock Liabilities were $228.8 million in Q2 2025, $193.2 million in Q1 2025, and $190.2 million in Q4 2024.